Defunct Company
Total Trials
4
As Lead Sponsor
3
As Collaborator
1
Total Enrollment
709
NCT00404014
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 31, 2006
Completion: Jun 30, 2008
NCT00422981
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
Start: Jan 31, 2007
Completion: Jan 31, 2008
NCT01110720
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Phase: Phase 2/3
Start: Oct 31, 2010
Completion: Dec 31, 2012
NCT06594211
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
Phase: N/A
Role: Collaborator
Start: Oct 9, 2024
Completion: Oct 9, 2028